Effect of Chronic Kidney Failure Stage on Blood Levels of Kinase Inhibitors Pazopanib and Cabozantinib in Metastatic Kidney Cancer Treatment

What this Trial Is About

Researchers are studying the impact of chronic kidney failure on the blood levels and effects of two kinase inhibitors, pazopanib and cabozantinib, used to treat patients with metastatic kidney cancer. The goal is to understand how kidney function influences the drugs effectiveness and side effects. This study focuses on patients with normal kidney function or moderate to severe kidney failure, including those on dialysis. Participants take either pazopanib or cabozantinib daily for at least three months as prescribed by their doctors. Blood samples will be collected at one month and three months after starting treatment to measure the concentration of these drugs. These tests are in addition to routine blood tests and will help assess drug levels and tolerance according to kidney function. During the study, patients will attend scheduled visits for blood tests and clinical evaluations to monitor side effects and drug levels. Researchers will analyze blood concentrations and toxicity to propose potential dose adjustments. The primary outcome is measuring the drug concentration in the blood at one month, with additional assessments at three months. The study is sponsored by the Institut du Cancer de Montpellier - Val dAurelle and will continue until March 2026.

Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer